Connected scale measures more than 60 biomarkers, including cardiovascular function, vascular health, metabolism and cellular composition.
French healthtech Withings today announced the launch of its latest connected scale product at the CES 2026 tradeshow in Las Vegas, describing the product as a “home longevity station” geared towards early detection and monitoring of chronic disease risk. Scheduled for release in the second quarter of 2026, pending FDA clearance for certain metrics, the company claims the $600 Body Scan 2 provides “the ability to detect and reverse physiological imbalances at a reversible stage, years before symptoms appear.”
Withings launched its first connected scale in 2009, and Body Scan 2 builds on the same approach, using electrodes in contact with a user’s hands and feet to capture a wide array of physiological signals. According to the company, its latest offering goes far beyond weight management and provides a snapshot more than 60 biomarkers spanning cardiovascular function, vascular health, metabolism, cellular composition and early cardiometabolic risk.
“The most powerful place to reinvent preventive health is the connected scale,” said Withings founder Eric Carreel. “It’s the only moment where we naturally engage our whole body – hands, feet, posture – allowing us to capture more biomarkers in 90 seconds than any wearable can collect in weeks.”
Several new technologies have been incorporated into Body Scan 2, including impedance cardiography, which is used to assess how effectively the heart pumps blood, while a six-lead electrocardiogram evaluates electrical activity and rhythm. Together, these measurements provide indicators such as cardiac efficiency, cardiac reactivity and a derived “heart age.”
Body Scan 2 also introduces AI-enabled hypertension risk notification, and uses pulse wave velocity measurements taken across the arms and legs to estimate arterial elasticity and vascular age, mapping how stiff or flexible blood vessels are in different parts of the body. Another AI model enables assessment of glycemic regulation, seeking early signs of dysregulation rather than diagnosing diabetes.
In perhaps the most interesting new development, the scale leverages ultra-high-frequency bioimpedance spectroscopy to look beyond body weight and fat percentage, down to indicators of cellular health and metabolic efficiency. By analyzing how electrical currents pass through tissues at multiple frequencies, the system estimates active cell mass, cellular age and markers associated with metabolic slowdown or inflammation.
“The strongest predictors of long-term health decline appear years before symptoms,” said Dr Thomas Platzer, a member of the Scientific Advisory Board of the German Society of Anti-Aging Medicine. “Measuring cardiac function, arterial stiffness, cellular vitality, and metabolic activity in a longitudinal and integrated way gives us a level of early detection that was previously impossible outside clinical research. It has the potential to change prevention for millions of people.”
Emphasizing the importance of longitudinal patterns rather than single readings, Withings says it aims to establish individualized baselines for each user and monitor for deviations over time. A “health trajectory” score is designed to translate complex data into a clearer picture of how daily habits may be influencing a user’s healthspan.
Photographs courtesy of Withings